Monitor for actual execution of the sale via future Form 4 filings; given the officer status and recent pattern of insider selling, this may signal routine portfolio management rather than negative sentiment. However, traders should watch for cumulative insider outflows over time.
CYTK drugs
CYTK drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 8 $65.77entry
- T+1 · 7mo ago −1.79%α −2.37% · $64.59
- T+5 · 7mo ago −0.61%α −4.12% · $65.37
- T+20 · 7mo ago +17.21%α +8.67% · $77.09
- T+60 · 4mo ago +31.50%α +21.05% · $86.49
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Fady Malik, an officer at Cytokinetics, filed a Form 144 to notify intent to sell 22,000 shares of common stock, valued at approximately $1.43 million, acquired through stock option exercises. The filing is a routine notice of planned sales under Rule 144, with no indication of immediate market impact or unusual activity.
Key Facts
- Fady Malik, an officer of Cytokinetics, filed Form 144 to sell up to 22,000 shares.
- The shares are to be sold on the NASDAQ, with an approximate value of $1.43 million based on current market prices.
- Shares were acquired through the exercise of stock options on March 9 and March 17, 2026, and will be sold for cash.
- This is an advance notice of intent to sell; actual sale may not occur immediately or at all.
- Recent insider activity shows $2.9M in insider sells over the past 30 days, indicating ongoing routine selling.
Financial Impact
$1.43 million in potential share sales (22,000 shares), representing a small fraction of the company's $8.0B market cap.
Risk Factors
- Potential downward price pressure if the full 22,000 shares are sold quickly.
- Perception of insider pessimism if combined with other negative catalysts, though standalone impact is minimal.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-003289 |
| Document: 0001950047-26-003289-index.html | 0001950047-26-003289 |
| Document: 0001950047-26-003289.txt | 0001950047-26-003289 |
Track record
46 reports on CYTK
7 of 11 bullish or bearish reports moved the stock their way by T+20. Best: +8.59% at T+20 after the Sep 15, 2026 report. 10 of 11 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $53.76 Now $53.17 −1.10% settles Dec 15
- Nov 12, 20264d ago Insider Cluster Neutral 3/10 Entry $56.13 Now $53.17 −5.27% settles Dec 14
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $56.18 Now $53.17 −5.36% settles Dec 9
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $56.18 Now $53.17 −5.36% settles Dec 9
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $55.14 Now $53.17 −3.57% settles Dec 8
- Nov 9, 20267d ago Press Release Neutral 4/10 Entry $55.14 Now $53.17 −3.57% settles Dec 8
- Nov 4, 202612d ago 8-K Bullish 6/10 No price data
- Nov 4, 202612d ago Press Release Neutral 5/10 Entry $55.55 Now $53.17 −4.28% settles Dec 4
- Nov 3, 202613d ago Insider Cluster Neutral 2/10 Entry $63.60 Now $53.17 −16.40% settles Dec 3
- Nov 2, 202614d ago Press Release Neutral 3/10 Entry $62.03 Now $53.17 −14.28% settles Dec 1
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers